Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201444 | 0.94 | HDAC4 (0.32) | BACE1DRD2DRD1DRD4DRD5 | |
| SCHEMBL5830 | 0.93 | BACE1 (0.31) | BACE1 | |
| SCHEMBL12192210 | 0.93 | BACE1 (0.31) | BACE1 | |
| SCHEMBL16081682 | 0.93 | BACE1 (0.31) | BACE1 | |
| Formic Acid Methyl Ester SCHEMBL29203565 | 0.89 | — | — | |
| SCHEMBL12893294 | 0.86 | BACE1 (0.33) | BACE1DRD2DRD1DRD4DRD5 | |
| SCHEMBL15807044 | 0.85 | — | — | |
| SCHEMBL15214822 | 0.85 | HDAC4 (0.30) | — | |
| SCHEMBL12581509 | 0.85 | — | — | |
| SCHEMBL5936514 | 0.81 | CA2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214998-A1 | Novel forms of a multicyclic compound | CEPHALON, INC. (US) | 2012-08-23 | — | — | US | claimed |
| US-20020165411-A1 | Sterically hindered phosphine ligands and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-07 | — | — | US | claimed |
| WO-2002048160-A1 | STERICALLY HINDERED PHOSPHINE LIGANDS AND USES THEREOF | YALE UNIVERSITY (US) | 2002-06-20 | — | — | WO | claimed |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20240398757-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4380920-A1 | INHIBITORS FOR CORONAVIRUSES | Cocrystal Pharma, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-112262129-B | Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2023014758-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-16 | — | — | US | disclosed |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1592698-A2 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | Takasago International Corporation (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1556053-A1 | ANTIINFLAMMATION AGENTS | Amgen Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004072088-A2 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
| US-20020165411-A1 | Sterically hindered phosphine ligands and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-07 | — | — | US | disclosed |
| WO-2002048160-A1 | STERICALLY HINDERED PHOSPHINE LIGANDS AND USES THEREOF | YALE UNIVERSITY (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398757-A1 | INHIBITORS FOR CORONAVIRUSES | ACE, ACE2, SARS1 | BACE1 503/4885DRD2 4776/4885DRD1 4578/4885 |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | BACE1 2441/4885DRD2 2954/4885DRD1 2716/4885 |
| US-20020165411-A1 | Sterically hindered phosphine ligands and uses thereof | NRP1, NR2C2, CXCR1 | BACE1 887/4885DRD2 275/4885DRD1 176/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | BACE1 2108/4885DRD2 526/4885DRD1 346/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | BACE1 2411/4885DRD2 4435/4885DRD1 4439/4885 |
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | SQLE, C9, PHOSPHO1 | BACE1 2838/4885DRD2 31/4885DRD1 18/4885 |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH2 | BACE1 984/4885DRD2 528/4885DRD1 354/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | BACE1 1142/4885DRD2 975/4885DRD1 1957/4885 |
| US-20120214998-A1 | Novel forms of a multicyclic compound | CYP11B2, CYP11B1, CYP11A1 | BACE1 1391/4885DRD2 3815/4885DRD1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.